ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year
2024.06.27
Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance
2024.03.19
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024.03.18
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024.01.03
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2022-03-22
Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million
2021-12-20
Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value
2021-11-10
First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-10-27
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-08-12
Essex Bio-Technology Reports First Half 2021 Financial Results
2021-07-25
Essex Bio-Technology Listed on Two Authoritative Lists
2021-07-19
First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)
2021-04-30
Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting
<
1
2
3
4
5
6
7
...
9
>